ethambutol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
1073 74-55-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ethambutol
  • etambutol
  • diambutol
  • (S,S)-Ethambutol
  • ethambutol hydrochloride
  • ethambutol dihydrochloride
  • ethambutol HCl
An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863)
  • Molecular weight: 204.31
  • Formula: C10H24N2O2
  • CLOGP: 0.12
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 4
  • TPSA: 64.52
  • ALOGS: -1.43
  • ROTB: 9
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.20 g O
1.20 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 79 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 122.36 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 77 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.18 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.10 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.776 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.199 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 1.189 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 3.606 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 90.720 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 71.100 % High 1
herg hERG pIC50 3.723 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 2.704 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.565 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 85.250 % High 1
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK3,MAP2K6,MAP3K21,MAPK7,NTRK2,PDK2,PDK4,PIM2,PRKDC,SIK2,SYK,TEK,TGFBR1,ZAP70 32
kinase-selectivity-class ACVRL1,AKT3,CAMK2A,CAMK2D,CDK2,CDK4,CDK7,CHUK,EIF2AK3,EPHB4,GAK,INSR,IRAK4,MAP2K6,MELK,PDK4,PRKACA,PRKCD,PTK2,SIK2 20
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.713 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.667 High 1
mh-clint Mouse hepatocyte intrinsic clearance 15.849 High 1
mppb Mouse plasma protein binding (% unbound) 91.360 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.766 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 87.320 % High 1
rat-kpuu-brain Rat brain Kpuu 0.030 % High 1
rh-clint Rat hepatocyte intrinsic clearance 7.816 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 91.520 % High 1
rppb Rat plasma protein binding (% unbound) 87.110 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 849.180 uM High 1

Approvals:

DateAgencyCompanyOrphan
Nov. 6, 1967 FDA STI PHARMA LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 882.64 21.97 316 15277 42442 90570412
Drug resistance 813.82 21.97 273 15320 30176 90582678
Paradoxical drug reaction 589.44 21.97 147 15446 5619 90607235
Mycobacterium avium complex infection 401.45 21.97 101 15492 3997 90608857
Immune reconstitution inflammatory syndrome 392.41 21.97 111 15482 6908 90605946
Drug-induced liver injury 299.70 21.97 189 15404 90129 90522725
Drug interaction 291.05 21.97 294 15299 276159 90336695
Immune reconstitution inflammatory syndrome associated tuberculosis 255.44 21.97 48 15545 455 90612399
Acute hepatic failure 232.33 21.97 101 15492 22460 90590394
Pneumatosis intestinalis 217.89 21.97 60 15533 3377 90609477
Hepatotoxicity 201.42 21.97 115 15478 45727 90567127
Tuberculoma of central nervous system 198.42 21.97 37 15556 335 90612519
Optic neuropathy 189.21 21.97 51 15542 2647 90610207
Optic neuritis 171.32 21.97 64 15529 9614 90603240
Rash maculo-papular 136.45 21.97 86 15507 40847 90572007
Mycobacterial infection 119.19 21.97 34 15559 2176 90610678
Hypertransaminasaemia 119.18 21.97 57 15536 15768 90597086
Tuberculosis 118.87 21.97 53 15540 12496 90600358
Jaundice 117.69 21.97 72 15521 32445 90580409
Pathogen resistance 116.22 21.97 46 15547 8069 90604785
Ocular toxicity 112.71 21.97 28 15565 1049 90611805
Pulmonary tuberculosis 100.51 21.97 36 15557 4798 90608056
Drug ineffective 98.62 21.97 483 15110 1383815 89229039
Disseminated tuberculosis 97.63 21.97 32 15561 3267 90609587
Neuropathy peripheral 95.94 21.97 118 15475 136852 90476002
Hepatic encephalopathy 95.84 21.97 47 15546 13725 90599129
Mycobacterium abscessus infection 92.98 21.97 24 15569 1051 90611803
Disseminated mycobacterium avium complex infection 89.20 21.97 18 15575 254 90612600
Atypical mycobacterial infection 83.14 21.97 24 15569 1602 90611252
Transaminases increased 83.03 21.97 61 15532 37131 90575723
Product use in unapproved indication 81.51 21.97 179 15414 336057 90276797
Pancreatitis haemorrhagic 78.72 21.97 19 15574 630 90612224
Hepatocellular injury 77.37 21.97 53 15540 28905 90583949
Tinnitus 77.17 21.97 62 15531 43040 90569814
Eosinophilia 75.71 21.97 52 15541 28481 90584373
Hepatitis 75.51 21.97 76 15517 70663 90542191
Toxic optic neuropathy 72.63 21.97 15 15578 239 90612615
Deafness 69.29 21.97 45 15548 22469 90590385
Hepatic function abnormal 67.20 21.97 59 15534 46229 90566625
Ototoxicity 66.07 21.97 21 15572 1943 90610911
Drug ineffective for unapproved indication 61.08 21.97 66 15527 66578 90546276
Pulmonary cavitation 60.43 21.97 17 15576 1034 90611820
Pyrexia 59.76 21.97 248 15345 660237 89952617
Hepatic cytolysis 58.61 21.97 46 15547 30870 90581984
Hydrocephalus 58.55 21.97 26 15567 6068 90606786
Pain 56.66 21.97 53 15540 996288 89616566
Multiple-drug resistance 55.49 21.97 27 15566 7749 90605105
Drug level decreased 55.41 21.97 29 15564 9701 90603153
Granuloma 55 21.97 25 15568 6160 90606694
Multiple organ dysfunction syndrome 54.60 21.97 63 15530 68273 90544581
Visual acuity reduced 51.35 21.97 38 15555 23372 90589482
Infusion related reaction 50.96 21.97 6 15587 416774 90196080
Lymphadenitis 50.80 21.97 21 15572 4116 90608738
Deafness neurosensory 49.56 21.97 24 15569 6817 90606037
Hepatitis toxic 49.47 21.97 20 15573 3705 90609149
Pulmonary toxicity 48.13 21.97 28 15565 11503 90601351
Disease progression 48.05 21.97 92 15501 156523 90456331
Hepatitis B 45.74 21.97 20 15573 4499 90608355
Aspartate aminotransferase increased 45.39 21.97 71 15522 102866 90509988
Aspergillus infection 44.43 21.97 26 15567 10797 90602057
Atypical mycobacterium test positive 44.23 21.97 7 15586 20 90612834
Distributive shock 44.15 21.97 18 15575 3406 90609448
Meningitis tuberculous 44.08 21.97 12 15581 646 90612208
Electrocardiogram QT prolonged 43.70 21.97 58 15535 72398 90540456
Oedematous kidney 43.37 21.97 9 15584 147 90612707
Bronchiectasis 41.84 21.97 33 15560 22297 90590557
Sinusitis 41.78 21.97 5 15588 343083 90269771
Hepatitis fulminant 41.69 21.97 18 15575 3927 90608927
Pain in extremity 41.44 21.97 13 15580 450516 90162338
Tuberculosis gastrointestinal 39.71 21.97 10 15583 396 90612458
Haemoptysis 39.64 21.97 38 15555 33282 90579572
Lymphadenopathy 39.62 21.97 44 15549 45731 90567123
Off label use 38.68 21.97 322 15271 1101930 89510924
Pancytopenia 38.56 21.97 72 15521 120191 90492663
Alanine aminotransferase increased 38.13 21.97 71 15522 118267 90494587
Systemic lupus erythematosus 37.95 21.97 8 15585 361888 90250966
Dyschromatopsia 37.93 21.97 11 15582 746 90612108
Uveitis 37.57 21.97 27 15566 15876 90596978
Oedematous pancreatitis 37.54 21.97 11 15582 774 90612080
Drug intolerance 37.23 21.97 164 15429 447427 90165427
Alopecia 36.34 21.97 20 15573 495051 90117803
Joint swelling 35.98 21.97 21 15572 503279 90109575
Cholestatic liver injury 35.83 21.97 16 15577 3781 90609073
Hypertension 35.79 21.97 17 15576 457515 90155339
Acid fast bacilli infection 34.23 21.97 7 15586 106 90612748
Thrombocytopenia 33.44 21.97 95 15498 208630 90404224
Fall 33.19 21.97 21 15572 481789 90131065
Arthropathy 32.90 21.97 11 15582 366231 90246623
Neurotoxicity 32.43 21.97 28 15565 21439 90591415
Musculoskeletal stiffness 32.24 21.97 6 15587 296526 90316328
Lower respiratory tract infection 32.18 21.97 3 15590 250656 90362198
Visual field defect 31.50 21.97 18 15575 7148 90605706
Hepatic failure 30.67 21.97 36 15557 39692 90573162
Swelling 30.64 21.97 17 15576 419041 90193813
Contraindicated product administered 29.85 21.97 9 15584 320130 90292724
Leukopenia 29.45 21.97 58 15535 100652 90512202
Hyperbilirubinaemia 29.17 21.97 22 15571 13914 90598940
Haemolysis 28.64 21.97 18 15575 8492 90604362
Hepatitis cholestatic 28.54 21.97 18 15575 8543 90604311
Mycobacterium test positive 28.13 21.97 7 15586 264 90612590
Choroiditis 27.80 21.97 7 15586 277 90612577
Pigment nephropathy 27.59 21.97 5 15588 38 90612816
Rheumatoid arthritis 27.54 21.97 14 15579 362600 90250254
Productive cough 27.05 21.97 48 15545 77015 90535839
Nasopharyngitis 26.34 21.97 19 15574 407085 90205769
Pancreatitis acute 26.30 21.97 30 15563 32085 90580769
Type IV hypersensitivity reaction 26.13 21.97 13 15580 3913 90608941
Infection 26.01 21.97 15 15578 362079 90250775
Liver transplant rejection 25.46 21.97 10 15583 1718 90611136
Nephritic syndrome 25.31 21.97 7 15586 400 90612454
Mastitis bacterial 25.30 21.97 5 15588 63 90612791
Condition aggravated 25.23 21.97 182 15411 595363 90017491
Fatigue 25.06 21.97 108 15485 1153915 89458939
Hypersensitivity 24.80 21.97 25 15568 454652 90158202
Cough 24.68 21.97 127 15466 368835 90244019
Pericarditis 24.45 21.97 8 15585 270143 90342711
Lymph node tuberculosis 24.42 21.97 8 15585 815 90612039
Granulomatous lymphadenitis 24.09 21.97 6 15587 227 90612627
Atypical mycobacterial lower respiratory tract infection 24.07 21.97 6 15587 228 90612626
Memory impairment 23.69 21.97 3 15590 197241 90415613
Osteogenesis imperfecta 23.54 21.97 8 15585 912 90611942
Cryptococcosis 23.40 21.97 9 15584 1462 90611392
Peripheral swelling 23.35 21.97 22 15571 413084 90199770
Premature delivery 23.32 21.97 31 15562 38731 90574123
Immune system disorder 23.18 21.97 18 15575 11887 90600967
Hepatosplenomegaly 23.14 21.97 11 15582 2998 90609856
Visual impairment 22.92 21.97 62 15531 132303 90480551
Abdominal lymphadenopathy 22.77 21.97 8 15585 1007 90611847
Headache 22.41 21.97 75 15518 862671 89750183
Acute respiratory failure 22.33 21.97 32 15561 42886 90569968
Hyperuricaemia 22.08 21.97 14 15579 6705 90606149
Transplant rejection 22.08 21.97 18 15575 12740 90600114
Encephalitis 22.04 21.97 17 15576 11117 90601737

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Paradoxical drug reaction 1076.45 18.96 272 17187 4466 42599410
Immune reconstitution inflammatory syndrome 821.50 18.96 260 17199 9883 42593993
Drug-induced liver injury 524.61 18.96 273 17186 38000 42565876
Drug resistance 434.30 18.96 232 17227 34016 42569860
Drug reaction with eosinophilia and systemic symptoms 368.96 18.96 224 17235 41851 42562025
Immune reconstitution inflammatory syndrome associated tuberculosis 316.91 18.96 68 17391 513 42603363
Hepatotoxicity 303.53 18.96 165 17294 25002 42578874
Optic neuropathy 213.95 18.96 67 17392 2445 42601431
Jaundice 195.31 18.96 140 17319 34449 42569427
Tuberculosis 194.63 18.96 91 17368 10008 42593868
Mycobacterial infection 193.62 18.96 63 17396 2605 42601271
Drug interaction 191.05 18.96 369 17090 266630 42337246
Mycobacterium avium complex infection 166.36 18.96 58 17401 2969 42600907
Tuberculoma of central nervous system 143.96 18.96 31 17428 238 42603638
Hepatitis 113.25 18.96 92 17367 27208 42576668
Drug ineffective 102.17 18.96 517 16942 629680 41974196
Optic neuritis 100.99 18.96 44 17415 4098 42599778
Condition aggravated 93.65 18.96 276 17183 260478 42343398
Drug level decreased 92.14 18.96 55 17404 9922 42593954
Atypical mycobacterial infection 90.04 18.96 30 17429 1336 42602540
Disseminated tuberculosis 88.96 18.96 36 17423 2788 42601088
Immune system disorder 88.03 18.96 45 17414 5999 42597877
Granuloma 82.77 18.96 38 17421 4003 42599873
Mycobacterium abscessus infection 72 18.96 22 17437 738 42603138
Pulmonary tuberculosis 71.65 18.96 38 17421 5463 42598413
Toxic optic neuropathy 69.18 18.96 23 17436 1017 42602859
Ototoxicity 67.64 18.96 28 17431 2297 42601579
Ocular toxicity 67.58 18.96 18 17441 364 42603512
Lymphadenopathy 66.46 18.96 75 17384 33290 42570586
Multiple-drug resistance 61.52 18.96 38 17421 7284 42596592
Acute hepatic failure 61.40 18.96 53 17406 17020 42586856
Death 58.85 18.96 64 17395 471121 42132755
Meningitis tuberculous 57.35 18.96 18 17441 661 42603215
Pathogen resistance 57.01 18.96 43 17416 11407 42592469
Hepatic failure 56.88 18.96 74 17385 38026 42565850
Hydrocephalus 54.80 18.96 33 17426 6045 42597831
Pyrexia 51.74 18.96 306 17153 393736 42210140
Liver function test abnormal 51.63 18.96 65 17394 32326 42571550
Tuberculosis of central nervous system 51.38 18.96 13 17446 213 42603663
Tuberculosis of eye 50.11 18.96 10 17449 50 42603826
Rash maculo-papular 50.10 18.96 69 17390 37434 42566442
Fall 49.81 18.96 17 17442 234503 42369373
Deafness neurosensory 49.13 18.96 26 17433 3720 42600156
Skin disorder 47.98 18.96 46 17413 16898 42586978
Phalangeal hypoplasia 47.24 18.96 10 17449 70 42603806
Atypical mycobacterium test positive 46.64 18.96 10 17449 75 42603801
Thalamic infarction 45.99 18.96 16 17443 813 42603063
Pancytopenia 44.37 18.96 127 17332 117616 42486260
Hepatic function abnormal 43.81 18.96 77 17382 51490 42552386
Product use in unapproved indication 43.67 18.96 170 17289 184286 42419590
Unmasking of previously unidentified disease 43.34 18.96 17 17442 1212 42602664
Pulmonary cavitation 42.37 18.96 17 17442 1287 42602589
Diaphragmatic injury 41.96 18.96 10 17449 126 42603750
Drug intolerance 40.81 18.96 97 17362 80327 42523549
Pain 40.73 18.96 25 17434 244823 42359053
Sideroblastic anaemia 40.71 18.96 12 17447 355 42603521
Electrocardiogram QT prolonged 39.96 18.96 71 17388 47874 42556002
Thrombocytopenia 38.43 18.96 167 17292 190112 42413764
Treatment failure 37.87 18.96 81 17378 62543 42541333
Tubulointerstitial nephritis 36.19 18.96 54 17405 31494 42572382
Urinary tract inflammation 36.00 18.96 10 17449 238 42603638
Tuberculosis gastrointestinal 35.68 18.96 10 17449 246 42603630
Pulmonary granuloma 35.06 18.96 16 17443 1661 42602215
Splenic embolism 34.15 18.96 10 17449 289 42603587
Cytomegalovirus chorioretinitis 33.91 18.96 22 17437 4589 42599287
Hepatocellular injury 33.79 18.96 45 17414 23633 42580243
Bone tuberculosis 33.72 18.96 11 17448 458 42603418
Granulomatous liver disease 33.05 18.96 12 17447 691 42603185
Herpes zoster meningoencephalitis 32.67 18.96 11 17448 506 42603370
Lymphopenia 32.35 18.96 42 17417 21521 42582355
Hepatic cytolysis 32.31 18.96 47 17412 26797 42577079
Deafness 32.25 18.96 33 17426 13107 42590769
Febrile neutropenia 32.22 18.96 18 17441 185685 42418191
Acid fast bacilli infection 32.09 18.96 8 17451 123 42603753
Blindness 31.75 18.96 38 17421 17940 42585936
Drug eruption 31.63 18.96 43 17416 23032 42580844
Vitamin B1 decreased 31.61 18.96 10 17449 377 42603499
Pneumatosis intestinalis 30.91 18.96 21 17438 4731 42599145
Congenital foot malformation 30.37 18.96 10 17449 429 42603447
Chylothorax 30.35 18.96 13 17446 1161 42602715
Hepatitis fulminant 30.09 18.96 21 17438 4938 42598938
Eosinophilia 29.07 18.96 50 17409 32849 42571027
Gastrointestinal disorder 28.96 18.96 61 17398 46592 42557284
Liver transplant rejection 28.93 18.96 16 17443 2497 42601379
Nephropathy toxic 28.77 18.96 35 17424 16803 42587073
Haemoptysis 28.24 18.96 60 17399 46107 42557769
Product dose omission issue 28.19 18.96 14 17445 154351 42449525
Deafness bilateral 28.18 18.96 13 17446 1384 42602492
Atrial fibrillation 28.11 18.96 11 17448 139582 42464294
Transaminases increased 27.78 18.96 49 17410 32836 42571040
Papilloma 27.77 18.96 9 17450 367 42603509
Diarrhoea 27.43 18.96 97 17362 460752 42143124
Colour blindness 27.29 18.96 9 17450 388 42603488
Mixed liver injury 27.28 18.96 19 17440 4455 42599421
Cholestasis 26.50 18.96 48 17411 32831 42571045
Malignant neoplasm progression 26.44 18.96 6 17453 108394 42495482
Encephalitis 26.18 18.96 25 17434 9133 42594743
Blood pressure increased 26.18 18.96 5 17454 101923 42501953
Hypermetabolism 25.64 18.96 8 17451 288 42603588
Hyperuricaemia 25.58 18.96 25 17434 9399 42594477
Accelerated hypertension 25.45 18.96 8 17451 295 42603581
Conductive deafness 24.96 18.96 9 17450 508 42603368
Immunosuppressant drug level decreased 24.89 18.96 13 17446 1811 42602065
Cachexia 24.85 18.96 23 17436 8081 42595795
Lymph node tuberculosis 24.79 18.96 9 17450 518 42603358
Cardiac failure congestive 24.72 18.96 3 17456 85599 42518277
Visual acuity reduced 24.50 18.96 33 17426 17517 42586359
Dyschromatopsia 24.43 18.96 9 17450 540 42603336
Nasopharyngitis 24.12 18.96 3 17456 83993 42519883
Splenic infarction 24.01 18.96 14 17445 2417 42601459
Leukopenia 23.77 18.96 76 17383 74670 42529206
Constipation 23.75 18.96 19 17440 162272 42441604
Bovine tuberculosis 23.56 18.96 6 17453 101 42603775
Macular degeneration 23.43 18.96 14 17445 2527 42601349
Optic atrophy 23.26 18.96 11 17448 1238 42602638
Antibiotic level above therapeutic 22.87 18.96 8 17451 413 42603463
Cutaneous tuberculosis 22.18 18.96 6 17453 129 42603747
Immune thrombocytopenia 21.96 18.96 25 17434 11191 42592685
Fatigue 21.90 18.96 98 17361 435543 42168333
Infective aneurysm 21.81 18.96 10 17449 1049 42602827
Neuropathy peripheral 21.76 18.96 91 17368 101762 42502114
Pulmonary sequestration 21.69 18.96 5 17454 54 42603822
Drug ineffective for unapproved indication 21.61 18.96 54 17405 46109 42557767
Palpable purpura 21.51 18.96 7 17452 289 42603587
Autoimmune haemolytic anaemia 21.19 18.96 18 17441 5653 42598223
Implant site infection 20.94 18.96 10 17449 1151 42602725
Dilatation intrahepatic duct acquired 20.49 18.96 5 17454 70 42603806
Type III immune complex mediated reaction 20.35 18.96 8 17451 574 42603302
Trisomy 21 20.35 18.96 8 17451 574 42603302
Dizziness 20.33 18.96 45 17414 249209 42354667
Henoch-Schonlein purpura 20.23 18.96 12 17447 2138 42601738
Myocardial infarction 20.12 18.96 13 17446 123996 42479880
Marrow hyperplasia 19.96 18.96 10 17449 1277 42602599
Adrenocortical insufficiency acute 19.90 18.96 12 17447 2203 42601673
Pericarditis tuberculous 19.87 18.96 5 17454 80 42603796
Anxiety 19.83 18.96 12 17447 118548 42485328
Renal atrophy 19.81 18.96 10 17449 1297 42602579
Visual impairment 19.73 18.96 50 17409 43063 42560813
Splenic abscess 19.40 18.96 8 17451 650 42603226
Liver disorder 19.21 18.96 47 17412 39597 42564279
Osteolysis 19.06 18.96 14 17445 3566 42600310

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Paradoxical drug reaction 1565.68 16.48 392 29939 9425 110549543
Immune reconstitution inflammatory syndrome 1192.93 16.48 352 29979 15874 110543094
Drug reaction with eosinophilia and systemic symptoms 1186.78 16.48 535 29796 81560 110477408
Drug resistance 948.65 16.48 409 29922 55965 110503003
Drug-induced liver injury 741.54 16.48 442 29889 119625 110439343
Immune reconstitution inflammatory syndrome associated tuberculosis 561.93 16.48 113 30218 941 110558027
Hepatotoxicity 511.08 16.48 278 30053 63122 110495846
Drug interaction 505.89 16.48 652 29679 499531 110059437
Mycobacterium avium complex infection 390.44 16.48 118 30213 5759 110553209
Optic neuropathy 381.58 16.48 110 30221 4548 110554420
Jaundice 341.74 16.48 209 30122 59027 110499941
Tuberculoma of central nervous system 322.05 16.48 65 30266 552 110558416
Tuberculosis 311.88 16.48 133 30198 17641 110541327
Acute hepatic failure 302.32 16.48 163 30168 36305 110522663
Mycobacterial infection 260.73 16.48 81 30250 4336 110554632
Optic neuritis 245.02 16.48 98 30233 11049 110547919
Toxic optic neuropathy 216.36 16.48 54 30277 1274 110557694
Pneumatosis intestinalis 205.02 16.48 80 30251 8449 110550519
Drug ineffective 182.03 16.48 859 29472 1519681 109039287
Pulmonary tuberculosis 179.09 16.48 74 30257 9065 110549903
Rash maculo-papular 176.25 16.48 153 30178 74069 110484899
Disseminated tuberculosis 155.28 16.48 57 30274 5089 110553879
Atypical mycobacterial infection 144.41 16.48 46 30285 2672 110556296
Drug level decreased 142.85 16.48 79 30252 18469 110540499
Ocular toxicity 138.71 16.48 38 30293 1300 110557668
Hepatitis 138.36 16.48 146 30185 89908 110469060
Granuloma 134.07 16.48 61 30270 9429 110549539
Pathogen resistance 132.63 16.48 74 30257 17598 110541370
Pyrexia 120.63 16.48 526 29805 897739 109661229
Immune system disorder 119.30 16.48 63 30268 13438 110545530
Neuropathy peripheral 117.69 16.48 191 30140 179086 110379882
Lymphadenopathy 111.66 16.48 111 30220 63724 110495244
Hepatic function abnormal 108.35 16.48 128 30203 89167 110469801
Mycobacterium abscessus infection 107.93 16.48 33 30298 1673 110557295
Hepatic failure 106.56 16.48 112 30219 68627 110490341
Meningitis tuberculous 103.85 16.48 30 30301 1248 110557720
Transaminases increased 103.14 16.48 106 30225 63284 110495684
Eosinophilia 101.80 16.48 101 30230 57835 110501133
Hepatocellular injury 101.66 16.48 95 30236 50547 110508421
Pain 101.49 16.48 69 30262 954886 109604082
Hypertransaminasaemia 101.47 16.48 70 30261 24185 110534783
Multiple-drug resistance 98.17 16.48 55 30276 13180 110545788
Ototoxicity 96.64 16.48 38 30293 4093 110554875
Hydrocephalus 96.20 16.48 50 30281 10325 110548643
Deafness neurosensory 91.03 16.48 47 30284 9572 110549396
Hepatic cytolysis 89.45 16.48 92 30239 54961 110504007
Disseminated mycobacterium avium complex infection 89.08 16.48 22 30309 496 110558472
Hepatic encephalopathy 87.50 16.48 68 30263 28188 110530780
Thrombocytopenia 87.14 16.48 251 30080 348634 110210334
Fall 86.31 16.48 29 30302 603453 109955515
Visual acuity reduced 83.86 16.48 70 30261 32103 110526865
Electrocardiogram QT prolonged 82.48 16.48 124 30207 108836 110450132
Infusion related reaction 81.55 16.48 6 30325 381156 110177812
Pancytopenia 78.64 16.48 176 30155 209437 110349531
Condition aggravated 77.77 16.48 402 29929 734434 109824534
Product use in unapproved indication 70.83 16.48 276 30055 447101 110111867
Hepatitis fulminant 67.39 16.48 37 30294 8523 110550445
Tuberculosis gastrointestinal 66.21 16.48 18 30313 598 110558370
Pancreatitis haemorrhagic 65.76 16.48 20 30311 996 110557972
Nasopharyngitis 65.68 16.48 14 30317 394347 110164621
Deafness 65.27 16.48 56 30275 26653 110532315
Fatigue 60.27 16.48 155 30176 1215803 109343165
Lymph node tuberculosis 59.95 16.48 19 30312 1085 110557883
Joint swelling 58.70 16.48 24 30307 442821 110116147
Liver transplant rejection 57.93 16.48 26 30305 3892 110555076
Pulmonary cavitation 57.79 16.48 22 30309 2172 110556796
Dyschromatopsia 56.99 16.48 19 30312 1275 110557693
Tubulointerstitial nephritis 56.42 16.48 72 30259 54212 110504756
Hepatitis toxic 56.23 16.48 29 30302 5892 110553076
Unmasking of previously unidentified disease 55.43 16.48 23 30308 2845 110556123
Tuberculosis of central nervous system 54.50 16.48 15 30316 522 110558446
Lower respiratory tract infection 54.44 16.48 3 30328 243103 110315865
Completed suicide 54.25 16.48 3 30328 242378 110316590
Mobility decreased 52.95 16.48 3 30328 237419 110321549
Liver function test abnormal 52.92 16.48 79 30252 68871 110490097
Sinusitis 52.64 16.48 9 30322 296679 110262289
Alanine aminotransferase increased 52.54 16.48 139 30192 183634 110375334
Sideroblastic anaemia 52.40 16.48 14 30317 435 110558533
Contusion 51.88 16.48 3 30328 233358 110325610
Acid fast bacilli infection 51.36 16.48 12 30319 212 110558756
Hyperbilirubinaemia 51.17 16.48 52 30279 30619 110528349
Atypical mycobacterium test positive 50.41 16.48 10 30321 77 110558891
Cholestasis 49.63 16.48 74 30257 64444 110494524
Immunosuppressant drug level decreased 49.47 16.48 21 30310 2750 110556218
Hyperuricaemia 49.45 16.48 37 30294 14494 110544474
Tinnitus 48.82 16.48 71 30260 60469 110498499
Cholestatic liver injury 47.61 16.48 28 30303 7348 110551620
Aspergillus infection 47.49 16.48 46 30285 25570 110533398
Encephalitis 47.05 16.48 40 30291 18799 110540169
Arthropathy 46.27 16.48 11 30320 287511 110271457
Mixed liver injury 46.18 16.48 33 30298 12046 110546922
Diaphragmatic injury 45.95 16.48 10 30321 126 110558842
Pain in extremity 45.51 16.48 40 30291 487078 110071890
Product dose omission issue 45.02 16.48 16 30315 321766 110237202
Alopecia 44.82 16.48 22 30309 364731 110194237
Thalamic infarction 44.61 16.48 16 30315 1336 110557632
Pemphigus 44.14 16.48 4 30327 214566 110344402
Deafness bilateral 43.37 16.48 19 30312 2685 110556283
Skin disorder 43.15 16.48 56 30275 42857 110516111
Leukopenia 42.99 16.48 113 30218 148678 110410290
Systemic lupus erythematosus 42.39 16.48 9 30322 254329 110304639
Impaired healing 42.33 16.48 3 30328 196714 110362254
Stomatitis 42.20 16.48 11 30320 270231 110288737
Granulomatous liver disease 42.14 16.48 16 30315 1568 110557400
Death 41.98 16.48 80 30251 698789 109860179
Rheumatoid arthritis 41.74 16.48 15 30316 299598 110259370
Discomfort 41.60 16.48 5 30326 214702 110344266
Hepatitis cholestatic 41.24 16.48 36 30295 17530 110541438
Nephropathy toxic 41.19 16.48 44 30287 27434 110531534
Splenic embolism 40.90 16.48 10 30321 216 110558752
Aspartate aminotransferase increased 40.76 16.48 116 30215 159820 110399148
Drug eruption 40.49 16.48 61 30270 53598 110505370
Herpes zoster meningoencephalitis 40.31 16.48 14 30317 1064 110557904
Drug ineffective for unapproved indication 39.26 16.48 87 30244 102751 110456217
Hypersensitivity 39.16 16.48 32 30299 403966 110155002
Blindness 39.01 16.48 49 30282 36310 110522658
Muscle spasms 38.62 16.48 14 30317 278143 110280825
Peripheral swelling 37.94 16.48 33 30298 404001 110154967
Haemophagocytic lymphohistiocytosis 37.86 16.48 45 30286 31514 110527454
Tuberculosis of eye 37.84 16.48 8 30323 87 110558881
Treatment noncompliance 37.69 16.48 70 30261 72920 110486048
Splenic abscess 37.44 16.48 13 30318 987 110557981
Bone tuberculosis 37.19 16.48 12 30319 726 110558242
Contraindicated product administered 37.09 16.48 11 30320 248256 110310712
Wheezing 36.89 16.48 12 30319 255218 110303750
Headache 36.68 16.48 122 30209 882255 109676713
Hypertension 36.56 16.48 52 30279 510032 110048936
Uveitis 36.56 16.48 37 30294 21673 110537295
Constipation 36.37 16.48 27 30304 357759 110201209
Hilar lymphadenopathy 36.36 16.48 16 30315 2286 110556682
Asthma 35.77 16.48 12 30319 250279 110308689
Visual impairment 35.72 16.48 99 30232 134329 110424639
Musculoskeletal stiffness 35.72 16.48 16 30315 279806 110279162
Disseminated intravascular coagulation 35.61 16.48 50 30281 41236 110517732
Colour blindness 35.58 16.48 11 30320 579 110558389
Cachexia 35.35 16.48 29 30302 12976 110545992
Urinary tract inflammation 35.29 16.48 10 30321 388 110558580
Memory impairment 34.87 16.48 6 30325 196938 110362030
Pulmonary granuloma 34.72 16.48 16 30315 2545 110556423
Oedematous kidney 34.28 16.48 9 30322 261 110558707
Off label use 34.27 16.48 589 29742 1499596 109059372
Type IV hypersensitivity reaction 34.02 16.48 21 30310 6012 110552956
Haemoptysis 33.84 16.48 66 30265 71288 110487680
Hepatosplenomegaly 33.81 16.48 22 30309 6897 110552071
Dizziness 33.71 16.48 90 30241 698103 109860865
Neurotoxicity 33.30 16.48 49 30282 42158 110516810
Lymphadenitis 33.23 16.48 20 30311 5473 110553495
Cytomegalovirus chorioretinitis 33.22 16.48 22 30309 7106 110551862
Conductive deafness 33.10 16.48 9 30322 299 110558669
Transplant rejection 32.77 16.48 37 30294 24530 110534438
Psoriatic arthropathy 32.70 16.48 7 30324 196754 110362214
Injection site pain 32.44 16.48 5 30326 177917 110381051
Multiple organ dysfunction syndrome 32.03 16.48 103 30228 151607 110407361
Immune thrombocytopenia 31.93 16.48 35 30296 22459 110536509
Blood cholesterol increased 31.91 16.48 6 30325 184779 110374189
Optic atrophy 31.85 16.48 15 30316 2506 110556462
Adrenocortical insufficiency acute 31.70 16.48 18 30313 4422 110554546
Peritoneal tuberculosis 31.40 16.48 10 30321 580 110558388
Cryptococcosis 31.00 16.48 18 30313 4613 110554355
Hypermetabolism 30.87 16.48 10 30321 613 110558355
Weight increased 30.84 16.48 42 30289 419602 110139366
Lymphopenia 30.78 16.48 46 30285 40124 110518844
Pericarditis tuberculous 30.38 16.48 7 30324 116 110558852
Intentional product use issue 30.37 16.48 15 30316 247891 110311077
Insomnia 29.75 16.48 33 30298 360557 110198411
Antipsychotic drug level decreased 29.59 16.48 12 30319 1400 110557568
Distributive shock 29.41 16.48 19 30312 5885 110553083
Sleep disorder 29.31 16.48 9 30322 198635 110360333
Infective aneurysm 28.95 16.48 12 30319 1480 110557488
Atypical mycobacterial lower respiratory tract infection 28.62 16.48 8 30323 295 110558673
Visual field defect 28.52 16.48 23 30308 10049 110548919
Blood pressure increased 28.24 16.48 18 30313 258355 110300613
Lymphadenopathy mediastinal 28.19 16.48 18 30313 5466 110553502
Disease progression 28.15 16.48 137 30194 243897 110315071
Papilloma 28.10 16.48 9 30322 532 110558436
Bovine tuberculosis 28.09 16.48 7 30324 164 110558804
Pulmonary toxicity 27.64 16.48 29 30302 17717 110541251
Malignant neoplasm progression 27.45 16.48 7 30324 174560 110384408
Hepatitis B 27.32 16.48 22 30309 9590 110549378
Anti-cyclic citrullinated peptide antibody positive 27.30 16.48 8 30323 181976 110376992
Dyspnoea 27.19 16.48 185 30146 1106687 109452281
HIV infection 27.06 16.48 11 30320 1292 110557676
Bradycardia 26.96 16.48 5 30326 155512 110403456
Anxiety 26.94 16.48 33 30298 345045 110213923
Vitamin B1 decreased 26.85 16.48 10 30321 929 110558039
Mycobacterium test positive 26.60 16.48 9 30322 632 110558336
Pulmonary sequestration 26.58 16.48 5 30326 28 110558940
Intentional overdose 25.88 16.48 3 30328 132498 110426470
Pericarditis 25.73 16.48 14 30317 219100 110339868
Granulomatous lymphadenitis 25.38 16.48 8 30323 449 110558519
Haemolytic anaemia 25.37 16.48 30 30301 20890 110538078
Psoriasis 25.37 16.48 4 30327 139989 110418979
Bronchitis 25.27 16.48 6 30325 157026 110401942
Clostridium difficile colitis 25.17 16.48 44 30287 43734 110515234
Depression 25.14 16.48 30 30301 317305 110241663
Atrial fibrillation 25.10 16.48 16 30315 229626 110329342
Infection 24.89 16.48 38 30293 362162 110196806
Accelerated hypertension 24.68 16.48 9 30322 788 110558180
Splenomegaly 24.68 16.48 32 30299 24466 110534502
Oedematous pancreatitis 24.53 16.48 11 30320 1643 110557325
Gait inability 24.48 16.48 4 30327 136372 110422596
Palpable purpura 24.47 16.48 8 30323 505 110558463
Jarisch-Herxheimer reaction 24.33 16.48 10 30321 1207 110557761
Cutaneous tuberculosis 24.26 16.48 7 30324 290 110558678
Musculoskeletal pain 24.09 16.48 10 30321 183013 110375955
Febrile neutropenia 23.98 16.48 31 30300 316736 110242232
Oesophageal candidiasis 23.84 16.48 22 30309 11512 110547456
Lichenoid keratosis 23.59 16.48 17 30314 6285 110552683
Iridocyclitis 23.54 16.48 16 30315 5392 110553576
Blister 23.30 16.48 17 30314 227359 110331609
Mastitis bacterial 22.98 16.48 5 30326 63 110558905
Lymph node abscess 22.98 16.48 5 30326 63 110558905
Brain oedema 22.96 16.48 35 30296 31063 110527905
Bursitis 22.90 16.48 4 30327 129914 110429054
Therapeutic product effect decreased 22.86 16.48 20 30311 244296 110314672
Abdominal discomfort 22.82 16.48 46 30285 393812 110165156
Urinary tract infection 22.64 16.48 34 30297 326248 110232720
Pigment nephropathy 22.36 16.48 5 30326 72 110558896
Rash morbilliform 22.18 16.48 18 30313 7933 110551035
Feeling abnormal 22.03 16.48 11 30320 180700 110378268
Implant site infection 22.01 16.48 11 30320 2092 110556876
Dry mouth 21.75 16.48 14 30317 199934 110359034
Toxic epidermal necrolysis 21.65 16.48 48 30283 56679 110502289
Choroiditis 21.61 16.48 10 30321 1605 110557363
Hereditary optic atrophy 21.42 16.48 5 30326 88 110558880
Dyspepsia 21.29 16.48 13 30318 190952 110368016
Diarrhoea 21.28 16.48 205 30126 1139300 109419668
Rheumatoid factor positive 21.24 16.48 5 30326 131635 110427333
Hemianopia heteronymous 21.21 16.48 5 30326 92 110558876
Upper respiratory tract infection 21.16 16.48 5 30326 131323 110427645
Osteogenesis imperfecta 21.10 16.48 8 30323 781 110558187
Phalangeal hypoplasia 21.03 16.48 4 30327 24 110558944
Axonal neuropathy 21.00 16.48 11 30320 2307 110556661
Marrow hyperplasia 20.60 16.48 10 30321 1786 110557182
Nephritic syndrome 20.56 16.48 7 30324 501 110558467
Visual pathway disorder 20.49 16.48 5 30326 107 110558861
Neutropenia 20.49 16.48 174 30157 374446 110184522
Dermatitis exfoliative 20.33 16.48 20 30311 11327 110547641
Oropharyngeal pain 20.19 16.48 6 30325 135270 110423698
Confusional state 19.98 16.48 64 30267 468616 110090352
Testicular mass 19.95 16.48 5 30326 120 110558848
Inappropriate schedule of product administration 19.88 16.48 16 30315 203621 110355347
Congenital foot malformation 19.81 16.48 4 30327 34 110558934
Pancreatitis acute 19.71 16.48 48 30283 60226 110498742
Pneumothorax 19.68 16.48 35 30296 35250 110523718
Road traffic accident 19.61 16.48 3 30328 107395 110451573
Osteoarthritis 19.58 16.48 13 30318 182610 110376358
Corneal deposits 19.46 16.48 7 30324 589 110558379
Haematochezia 19.42 16.48 4 30327 115520 110443448
Stevens-Johnson syndrome 19.40 16.48 41 30290 46860 110512108
Drug hypersensitivity 19.36 16.48 62 30269 454028 110104940
Cerebrovascular accident 19.30 16.48 13 30318 181271 110377697
Blood bilirubin increased 19.24 16.48 55 30276 75917 110483051
Splenic infarction 19.18 16.48 13 30318 4361 110554607
Psoas abscess 19.17 16.48 9 30322 1493 110557475
Amnesia 19.12 16.48 3 30328 105405 110453563
Stress 19.11 16.48 3 30328 105345 110453623
Disseminated Bacillus Calmette-Guerin infection 19.08 16.48 6 30325 334 110558634
Renal impairment 19.07 16.48 102 30229 188343 110370625
Type I hypersensitivity 18.95 16.48 15 30316 6378 110552590
Hyperaldosteronism 18.82 16.48 7 30324 648 110558320
Henoch-Schonlein purpura 18.79 16.48 12 30319 3645 110555323
Respiratory failure 18.78 16.48 112 30219 215220 110343748
Overdose 18.62 16.48 22 30309 233772 110325196
Glomerulonephritis minimal lesion 18.59 16.48 8 30323 1083 110557885
Eosinophilic pustular folliculitis 18.57 16.48 5 30326 160 110558808
Loss of personal independence in daily activities 18.48 16.48 9 30322 150011 110408957
Rectal haemorrhage 18.46 16.48 5 30326 119828 110439140
Bronchopulmonary aspergillosis 18.46 16.48 31 30300 29832 110529136
Necrosis 18.41 16.48 19 30312 11387 110547581
Myopia 18.38 16.48 10 30321 2261 110556707
Coagulopathy 18.38 16.48 37 30294 40874 110518094
Macular degeneration 18.33 16.48 26 30305 21633 110537335
Tuberculous pleurisy 18.31 16.48 7 30324 699 110558269
Haemolysis 18.26 16.48 22 30309 15617 110543351
Fracture pain 18.20 16.48 8 30323 1140 110557828
AIDS related complication 18.20 16.48 4 30327 53 110558915
Influenza 18.18 16.48 12 30319 169089 110389879
Renal atrophy 18.08 16.48 10 30321 2336 110556632
Treatment failure 18.02 16.48 134 30197 277100 110281868
Swelling 17.87 16.48 44 30287 350997 110207971
Ascites 17.79 16.48 61 30270 92747 110466221
Autoimmune haemolytic anaemia 17.78 16.48 18 30313 10549 110548419
Gastrooesophageal reflux disease 17.74 16.48 14 30317 179962 110379006
Labelled drug-drug interaction medication error 17.56 16.48 30 30301 29272 110529696
Vision blurred 17.51 16.48 76 30255 128946 110430022
Tuberculid 17.45 16.48 3 30328 9 110558959
Purpura 17.37 16.48 27 30304 24361 110534607
Cardiac failure congestive 17.22 16.48 10 30321 150990 110407978
Toxic encephalopathy 17.11 16.48 21 30310 15193 110543775
Femoral artery aneurysm 17.04 16.48 5 30326 220 110558748
Papilloedema 17.02 16.48 15 30316 7394 110551574
Medication error 17.00 16.48 4 30327 105362 110453606
Joint tuberculosis 16.95 16.48 5 30326 224 110558744
Polyneuropathy 16.90 16.48 31 30300 31981 110526987
Pseudomembranous colitis 16.85 16.48 14 30317 6377 110552591
Nicotinic acid deficiency 16.80 16.48 5 30326 231 110558737
Subacute hepatic failure 16.78 16.48 5 30326 232 110558736
Substance-induced psychotic disorder 16.67 16.48 13 30318 5411 110553557
Incorrect dose administered 16.59 16.48 4 30327 103637 110455331

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J04AK02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Other drugs for treatment of tuberculosis
ATC J04AM03 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04AM06 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04AM07 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04AM09 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04AM10 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
FDA EPC N0000175483 Antimycobacterial
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000995 Antitubercular Agents
CHEBI has role CHEBI:33231 antitubercular agent
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:67079 anti-inflammatory agent
CHEBI has role CHEBI:78298 environmental contaminant
CHEBI has role CHEBI:64946 anti-HIV agent

Related Drugs by ATC class:

J04AK Other drugs for treatment of tuberculosis 7 drugs
bedaquilinedelamanidmorinamidepretomanidpyrazinamideterizidonethioacetazone
J04AM Combinations of drugs for treatment of tuberculosis 11 drugs
isoniazidlevofloxacinlomefloxacinprotionamidepyrazinamiderifabutinrifampicinstreptomycinsulfamethoxazolethioacetazonetrimethoprim

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute tuberculosis indication 25629007
Pulmonary tuberculosis indication 154283005 DOID:2957
Tuberculosis of meninges off-label use 58437007
Atypical mycobacterial infection off-label use 111812000
Pulmonary Mycobacterium avium complex infection off-label use 186342000
Diabetic retinopathy contraindication 4855003 DOID:8947
Optic neuritis contraindication 66760008 DOID:1210
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Bilateral cataracts contraindication 95722004




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.58 Basic
pKa2 5.58 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
5-hydroxytryptamine receptor 2A GPCR IC50 5.48 WOMBAT-PK
5-hydroxytryptamine receptor 2B GPCR IC50 5.15 WOMBAT-PK
5-hydroxytryptamine receptor 2C GPCR IC50 5.16 WOMBAT-PK
Cytochrome P450 3A4 Enzyme IC50 6.25 WOMBAT-PK
Cytochrome P450 3A5 Enzyme IC50 4.72 WOMBAT-PK
Probable arabinosyltransferase A Enzyme INHIBITOR CHEMBL CHEMBL
Probable arabinosyltransferase B Enzyme WOMBAT-PK
Probable arabinosyltransferase C Enzyme WOMBAT-PK
Probable arabinosyltransferase A Enzyme WOMBAT-PK

External reference:

IDSource
4019747 VUID
N0000147838 NUI
D00878 KEGG_DRUG
1070-11-7 SECONDARY_CAS_RN
4017912 VANDF
4019747 VANDF
C0014964 UMLSCUI
CHEBI:4877 CHEBI
95E PDB_CHEM_ID
CHEMBL44884 ChEMBL_ID
DB00330 DRUGBANK_ID
CHEMBL3140361 ChEMBL_ID
D004977 MESH_DESCRIPTOR_UI
14052 PUBCHEM_CID
12996 IUPHAR_LIGAND_ID
1074 INN_ID
8G167061QZ UNII
142435 RXNORM
32076 MMSL
4692 MMSL
d00068 MMSL
002850 NDDF
004868 NDDF
24450004 SNOMEDCT_US
26346008 SNOMEDCT_US
387129004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ETHAMBUTOL HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 10135-796 TABLET, FILM COATED 100 mg ORAL NDA 16 sections
ETHAMBUTOL HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 10135-797 TABLET, FILM COATED 400 mg ORAL NDA 16 sections
ETHAMBUTOL HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 42806-101 TABLET, FILM COATED 100 mg ORAL ANDA 17 sections
ETHAMBUTOL HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 42806-102 TABLET, FILM COATED 400 mg ORAL ANDA 17 sections
Ethambutol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-2337 TABLET, FILM COATED 100 mg ORAL NDA authorized generic 16 sections
Ethambutol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-3948 TABLET, FILM COATED 400 mg ORAL ANDA 18 sections
Ethambutol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-5142 TABLET 400 mg ORAL ANDA 16 sections
Ethambutol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 53808-0977 TABLET 400 mg ORAL NDA 10 sections
Myambutol HUMAN PRESCRIPTION DRUG LABEL 1 54868-2876 TABLET 400 mg ORAL NDA 17 sections
Ethambutol HUMAN PRESCRIPTION DRUG LABEL 1 54868-6219 TABLET, FILM COATED 400 mg ORAL ANDA 17 sections
Ethambutol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54879-001 TABLET, FILM COATED 100 mg ORAL NDA authorized generic 16 sections
Ethambutol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54879-002 TABLET, FILM COATED 400 mg ORAL NDA authorized generic 16 sections
Ethambutol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 55695-023 TABLET, FILM COATED 100 mg ORAL NDA authorized generic 16 sections
Ethambutol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 55695-035 TABLET, FILM COATED 400 mg ORAL NDA authorized generic 16 sections
Ethambutol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68084-280 TABLET 400 mg ORAL ANDA 17 sections
Ethambutol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68151-0149 TABLET 100 mg ORAL ANDA 16 sections
Ethambutol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68180-280 TABLET 100 mg ORAL ANDA 16 sections
Ethambutol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68180-280 TABLET 100 mg ORAL ANDA 16 sections
Ethambutol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68180-281 TABLET 400 mg ORAL ANDA 16 sections
Ethambutol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68180-281 TABLET 400 mg ORAL ANDA 16 sections
Ethambutol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68850-004 TABLET, FILM COATED 100 mg ORAL NDA authorized generic 16 sections
Ethambutol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68850-005 TABLET, FILM COATED 400 mg ORAL NDA authorized generic 16 sections
Ethambutol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 70518-2966 TABLET 400 mg ORAL ANDA 16 sections
Ethambutol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 70518-3662 TABLET 100 mg ORAL ANDA 16 sections
Ethambutol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 85742-005 TABLET, FILM COATED 100 mg ORAL NDA authorized generic 16 sections
Ethambutol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 85742-006 TABLET, FILM COATED 400 mg ORAL NDA 16 sections